Abselion is the biological sensor for rapid and cost-effective detection of biological substances.
Abselion has raised $8.4M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Abselion's investors include Parkwalk Advisors, Business Growth Fund, R42 Group, New Ground Ventures, M Ventures.
Abselion is headquartered in Cambridge, United Kingdom.
Abselion is the biological sensor for rapid and cost-effective detection of biological substances.
Abselion is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abselion — Funding & Investors." VCBacked, December 4, 2024, https://www.vcbacked.co/company/abselion. Accessed July 20, 2026.
VCBacked. (2024). Abselion — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/abselion
{{cite web |title=Abselion — Funding & Investors |url=https://www.vcbacked.co/company/abselion |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated